[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

[#item_full_content]

Banks are reporting a ten-fold surge in digital scams, cybersecurity firm BioCatch says

[#item_full_content]Banks are under pressure to kick criminals off their platforms and compensate more victims as regulators…

x2VOL Surpasses 75 Million Approved Hours in Student Service in Schools Across the U.S.

[#item_full_content]DALLAS–(BUSINESS WIRE)– #ccr–x2VOL tracked over 75 million approved hours of student service, giving valuable information to…

Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

[#item_full_content]SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development…

[#item_full_content]

[#item_full_content]